Authors

Latest:

Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

Paul Mayor, MD

Latest:

Dr. Mayor on Neuroendocrine Carcinoma in Gynecologic Tumors

Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

Paul Nathan, MBBS, PhD, FRCP, Mount Vernon Cancer Centre

Latest:

Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal Melanoma

Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.

Paul Nghiem, MD, PhD

Latest:

Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma

Paul Oberstein, MD, NYU Langone Perlmutter Cancer Center

Paul R. Eber, MD

Latest:

Dr. Eber on Takeaways From the CARMENA Trial in mRCC

Paul R. Eber, MD, a urologist at Conrad-Pearson Clinic, discusses takeaways from the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Paul R. Helft, MD

Latest:

Dr. Helft Discusses Pancreatic and Carcinoid NETs

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses pancreatic and carcinoid neuroendocrine tumors.

Paul R. Helft, MD, Indiana School of Medicine of the Indiana University Melvin

Paul R. Sieber, MD

Latest:

Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADT

Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.

Paul R. Sieber, MD, FACS

Latest:

Maintaining Bone Health During ADT for Prostate Cancer

The use of androgen deprivation therapy in prostate cancer is now a well-established treatment regimen but is associated with an increased risk for bone fracture.

Paul Richardson, MD

Latest:

Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple Myeloma

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

Paul Richardson, MD, Dana-Farber Cancer Institute

Latest:

ASH Takeaways and Future Directions for Multiple Myeloma

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Paul Richardson, MD, Harvard Medical School

Paul Ruff, MD

Latest:

Dr. Ruff on the Timing of CRC Treatment With Aflibercept

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the decision regarding the timing of treatment with aflibercept for patients with colorectal cancer.

Paul Sabbatini, MD

Latest:

Dr. Sabbatini on Frontline Treatment of Newly Diagnosed Ovarian Cancer

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.

Paul W. Ladenson, MD

Latest:

Dr. Ladenson on Diagnosis of Thyroid Nodules

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

Paul W. Read, MD, PhD

Latest:

Rapid-Response System Enhances Palliative Care, Lowers Costs

A collaborative patient reported outcome-based care approach resulted in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients.

Paul Watson

Latest:

Companion Diagnostics Are Driving Support in the Evolving Regulatory Landscape

Owing to the high clinical failure rates, genetically variable tumor characteristics, and skyrocketing drug development costs, the era of traditional blockbuster oncology agents has come to an end.

Paula J. Bates, PhD

Latest:

Dr. Bates on Stimulating the Immune System With Nanoparticles in RCC

Paula J. Bates, PhD, discusses the use of nanoparticles to stimulate the immune system in renal cell carcinoma.

Paulo Marcelo Hoff, MD, PhD

Latest:

Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRC

Paulo Marcelo Hoff, MD, PhD, FACP, University of SÃ£o Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).